NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation

NNASDAQ:NMTC
0.75
USD
+0.00
(-0.01%)
-0.88EPS
26.46MMarket Cap
Dec 16Next Earn

Total Valuation

USD

As of June 30, 2026, NeuroOne Medical Technologies Corporation carries a market capitalization of 26.46M, placing it among publicly traded companies globally. Its enterprise value stands at 24.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap26.46M
Enterprise Value24.58M

Important Dates

NeuroOne Medical Technologies Corporation's next confirmed earnings release is scheduled for December 16, 2026.

Earnings Date12/16/2026

Share Statistics

As of June 30, 2026, NeuroOne Medical Technologies Corporation has 8.70M shares outstanding.

Shares Outstanding8.70M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 2.72, and the price-to-book ratio stands at 7.02.

PS Ratio2.72
PB Ratio7.02
P/TBV Ratio7.08
P/FCF Ratio-3.60
P/OCF Ratio-3.65

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 2.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 24.58M versus a market cap of 26.46M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.60

Financial Position

As of June 30, 2026, NeuroOne Medical Technologies Corporation maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

Current Ratio2.84
Quick Ratio1.54
Debt / Equity4.65
Debt / EBITDA-0.02

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, NeuroOne Medical Technologies Corporation posted a negative return on equity (ROE) of -124.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -87.56, reflecting losses generated across the asset base. The company generates approximately 526,039.72 in revenue per employee across its workforce of 18.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.01 indicates how many times NeuroOne Medical Technologies Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-124.66
Return on Assets (ROA)-87.56
Revenue Per Employee526,039.72
Employee Count18.00
Inventory Turnover2.01

Stock Price Statistics

USD

As of the close on November 16, 2026, NeuroOne Medical Technologies Corporation's stock has declined approximately 81.99% over the past 52 weeks. The 50-day moving average sits at 1.10, while the 200-day moving average is 2.96.

52-Week Price Change-81.99%
50-Day Moving Average1.10
200-Day Moving Average2.96

Income Statement

USD

Over the twelve months ended June 30, 2026, NeuroOne Medical Technologies Corporation generated 9.47M in revenue and converted that into -7.45M in net income, yielding earnings per share of -0.88. EBITDA reached -7.66M, while operating income came in at -7.90M.

Revenue9.47M
Gross Profit5.27M
Operating Income-7.90M
Pretax Income-7.45M
Net Income-7.45M
EBITDA-7.66M
EBIT-7.90M
Earnings Per Share (EPS)-0.88

Balance Sheet

USD

As of June 30, 2026, NeuroOne Medical Technologies Corporation holds 2.05M in cash and equivalents against 175,345.00 in total debt, resulting in a net debt position of -2.05M. Total book value stands at 3.77M, with working capital of 3.75M providing operational flexibility.

Cash & Cash Equivalents2.05M
Total Debt175,345.00
Net Debt-2.05M
Equity (Book Value)3.77M
Book Value Per Share0.43
Working Capital3.75M

Cash Flow

USD

NeuroOne Medical Technologies Corporation produced -7.05M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -109,536.00 in capital expenditures, free cash flow totaled -7.16M - equivalent to -0.85 per share.

Operating Cash Flow-7.05M
Capital Expenditures-109,536.00
Free Cash Flow-7.16M
FCF Per Share-0.85

Margins

Over the twelve months ended June 30, 2026, NeuroOne Medical Technologies Corporation posted a gross margin of 55.65, reflecting its pricing power and cost economics. The operating margin of -83.43 and net profit margin of -78.63 provide insight into operational efficiency.

Gross Margin55.65
Operating Margin-83.43
Pretax Margin-78.63
Profit Margin-78.63
EBITDA Margin-80.93

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -27.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.42, meaning NeuroOne Medical Technologies Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-4.42
FCF Yield-27.76

Stock Splits

NeuroOne Medical Technologies Corporation's most recent stock split took place on April 16, 2026 with a 6:1 split ratio.

Last Split Date4/16/2026
Split Ratio6:1

Scores

As of June 30, 2026, NeuroOne Medical Technologies Corporation has an Altman Z-Score of -14.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-14.60